1



                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                                  FORM 10-Q


           X  Quarterly report pursuant to Section 13 or 15(d) of the 
              Securities Exchange Act of 1934 

              For the quarterly period ended March 31, 1995 

                                   or

              Transition report pursuant to Section 13 or 15(d) of the
              Securities Exchange Act of 1934 

              For the transition period from      to      
          

              Commission File Number 1-87


                            EASTMAN KODAK COMPANY                 
            (Exact name of registrant as specified in its charter)


       NEW JERSEY                                        16-0417150    
(State of incorporation)                                 (IRS Employer
                                                         Identification No.)

343 STATE STREET, ROCHESTER, NEW YORK                       14650     
(Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code:         716-724-4000


Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 
1934 during the preceding 12 months, and (2) has been subject to such filing 
requirements for the past 90 days.  Yes  X        No     

Indicate the number of shares outstanding of each of the issuer's classes of 
common stock, as of the latest practicable date.


                                               Number of Shares Outstanding at
                Class                               March 31, 1995
     Common Stock, $2.50 par value                   340,333,003


                                                                     2

Eastman Kodak Company and Subsidiary Companies
CONSOLIDATED STATEMENT OF EARNINGS
First Quarter 1995 1994 (in millions) REVENUES Sales $3,137 $2,755 Earnings from equity interests and other revenues 72 24 ------ ------ TOTAL REVENUES 3,209 2,779 ------ ------ COSTS Cost of goods sold 1,613 1,470 Selling, general and administrative expenses 895 747 Research and development costs 219 204 Interest expense 19 57 Other charges 48 71 ------ ------ TOTAL COSTS 2,794 2,549 ------ ------ Earnings from continuing operations before income taxes 415 230 Provision for income taxes from continuing operations 153 85 ------ ------ Earnings from continuing operations before extraordinary item 262 145 Loss from discontinued operations - (51) ------ ------ Earnings before extraordinary item 262 94 Extraordinary item - (12) ------ ------ NET EARNINGS $ 262 $ 82 ====== ====== First Quarter 1995 1994 Primary earnings per share from continuing operations before extraordinary item $ .77 $ .44 Primary loss per share from discontinued operations - (.15) ------ ------ Primary earnings per share before extraordinary item .77 .29 Extraordinary item - (.04) ------ ------ Primary earnings per share $ .77 $ .25 ====== ====== Fully diluted earnings per share from continuing operations before extraordinary item $ .76 $ .43 Fully diluted loss per share from discontinued operations - (.15) ------ ------ Fully diluted earnings per share before extraordinary item .76 .28 Extraordinary item - (.04) ------ ------ Fully diluted earnings per share $ .76 $ .24 ====== ====== CONSOLIDATED STATEMENT OF RETAINED EARNINGS First Quarter 1995 1994 (in millions) Retained earnings at beginning of year $4,485 $4,469 Net earnings 262 82 Cash dividends declared (136) (132) Other changes (6) (2) ------ ------ RETAINED EARNINGS at end of quarter $4,605 $4,417 ====== ====== - - -------------------------------------------------------------------------------------- See Notes to Financial Statements
3 Eastman Kodak Company and Subsidiary Companies CONSOLIDATED STATEMENT OF FINANCIAL POSITION
March 31, Dec. 31, 1995 1994 (in millions) ASSETS CURRENT ASSETS Cash and cash equivalents $ 573 $ 2,020 Marketable securities 60 48 Receivables (net of allowances of $117 and $120) 2,855 3,064 Inventories 1,834 1,480 Deferred income tax charges 627 711 Other 353 360 ------- ------- Total current assets 6,302 7,683 PROPERTIES Land, buildings and equipment at cost 12,667 12,299 Less: Accumulated depreciation 7,261 7,007 ------- ------- Net properties 5,406 5,292 OTHER ASSETS Goodwill (net of accumulated amortization of $243 and $226) 623 616 Deferred income tax charges 475 505 Long-term receivables and other noncurrent assets 887 872 ------- ------- TOTAL ASSETS $13,693 $14,968 ======= ======= - - -------------------------------------------------------------------------------- LIABILITIES AND SHAREOWNERS' EQUITY CURRENT LIABILITIES Payables $ 3,212 $ 3,398 Short-term borrowings 373 371 Taxes-income and other 445 1,701 Dividends payable 136 136 Deferred income tax credits 21 129 ------- ------- Total current liabilities $ 4,187 $ 5,735 OTHER LIABILITIES Long-term borrowings 652 660 Postemployment liabilities 3,710 3,671 Other long-term liabilities 824 790 Deferred income tax credits 102 95 ------- ------- Total liabilities 9,475 10,951 SHAREOWNERS' EQUITY Common stock at par* 967 966 Additional capital paid in or transferred from retained earnings 533 515 Retained earnings 4,605 4,485 Accumulated translation adjustment 68 8 ------- ------- 6,173 5,974 Less: Treasury stock shares at cost* 1,955 1,957 ------- ------- Total shareowners' equity 4,218 4,017 ------- ------- TOTAL LIABILITIES AND SHAREOWNERS' EQUITY $13,693 $14,968 ======= ======= *Common stock: $2.50 par value, 950 million shares authorized, 386.9 million shares issued as of March 31, 1995. Treasury stock shares at cost consists of approximately 47 million shares at each balance sheet date. - - ------------------------------------------------------------------------------------------ See Notes to Financial Statements
4 Eastman Kodak Company and Subsidiary Companies CONSOLIDATED STATEMENT OF CASH FLOWS
First Quarter 1995 1994 (in millions) Cash flows from operating activities: Earnings from continuing operations before extraordinary item $ 262 $ 145 Adjustments to reconcile above earnings to net cash provided by (used in) operating activities: Depreciation and amortization 219 184 Benefit for deferred taxes (1) (11) Loss on sale and retirement of properties 19 13 Decrease in receivables 301 125 Increase in inventories (296) (189) Decrease in liabilities excluding borrowings (113) (299) Other items, net (187) 4 ------- ------- Total adjustments (58) (173) ------- ------- Net cash provided by (used in) operating activities 204 (28) ------- ------- Cash flows from investing activities: Additions to properties (238) (149) Proceeds from sale of properties 13 6 Marketable securities - purchases - (8) Marketable securities - sales 19 212 Cash flows related to sales of non-imaging health businesses (1,328) - ------- ------- Net cash (used in) provided by investing activities (1,534) 61 ------- ------- Cash flows from financing activities: Net (decrease) increase in borrowings with original maturity of 90 days or less (215) 34 Proceeds from other borrowings 217 - Repayment of other borrowings (8) (381) Dividends to shareowners (136) (165) Exercise of employee stock options 20 5 ------- ------- Net cash used in financing activities (122) (507) ------- ------- Effect of exchange rate changes on cash 5 2 ------- ------- Net decrease in cash and cash equivalents (1,447) (472) Cash and cash equivalents, beginning of year 2,020 1,635 ------- ------- Cash and cash equivalents, end of quarter $ 573 $ 1,163 ======= ======= - - ----------------------------------------------------------------------------------------- See Notes to Financial Statements
5 NOTES TO FINANCIAL STATEMENTS BASIS OF PRESENTATION The financial statements have been prepared by the Company in accordance with the accounting policies stated in the 1994 Annual Report and should be read in conjunction with the Notes to Financial Statements appearing therein. In the opinion of the Company, all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation have been included in the financial statements. The statements are based in part on estimates and have not been audited by independent accountants. The annual statements will be audited by independent accountants. - - ------------------------------------------------------------------------------ COMMITMENTS AND CONTINGENCIES The Company and its subsidiary companies are involved in lawsuits, claims, investigations and proceedings, including product liability, commercial, environmental, and health and safety matters, which are being handled and defended in the ordinary course of business. There are no such matters pending that the Company and its General Counsel expect to be material in relation to the Company's business, financial condition or results of operations. - - ------------------------------------------------------------------------------ RECLASSIFICATIONS Certain 1994 financial statement amounts have been reclassified to conform to the 1995 presentation. David J. FitzPatrick, Controller April 27, 1995 6 Management's Discussion and Analysis of Financial Condition and Results of Operations SUMMARY
(in millions, except earnings per share) First Quarter 1995 1994 Change Sales $3,137 $2,755 +14% Earnings (loss) from operations before extraordinary item: Continuing 262 145 Discontinued - (51) Net earnings 262 82 Primary earnings (loss) per share from operations before extraordinary item: Continuing .77 .44 Discontinued - (.15) Primary earnings per share .77 .25 Fully diluted earnings per share .76 .24
Sales for the first quarter of 1995 were $3,137 million, an increase of 14% over sales for the first quarter of 1994. Excluding the sales of Qualex (a U.S. photofinishing company which had been treated as an equity investment until the remainder of its outstanding shares were acquired in August, 1994), sales from continuing operations increased 9% over a year ago. Sales benefited from volume gains and the favorable effects of foreign currency rate changes, but were adversely affected by lower effective selling prices. Currency changes against the U.S. dollar favorably affected 1995 sales by approximately $127 million. Earnings from continuing operations before extraordinary item for the first quarter of 1995 were $262 million ($.77 per share), a sharp increase over earnings of $145 million ($.44 per share) in the first quarter last year. Earnings benefited from increased volumes, manufacturing productivity, the favorable effects of foreign currency rate changes, higher investment and other income, and lower interest expense. These benefits were partially offset by cost escalation, increased selling, general and administrative (SG&A) expenses and lower effective selling prices. During 1994, the Company divested the following non-imaging health businesses: the pharmaceutical and consumer health businesses of Sterling Winthrop Inc., the household products and do-it-yourself products businesses of L&F Products and the Clinical Diagnostic Division. These businesses have been reported as discontinued operations. As part of the divestitures, the Company announced on April 7, 1995, an agreement to sell its pharmaceutical research and development facility to SmithKline Beecham for $120 million. The proceeds from this sale did not differ materially from the Company's estimated proceeds for the sale of this facility. Net earnings for 1994 were reduced by an extraordinary charge of $12 million after-tax ($.04 per share) related to the early extinguishment of debt. - - ------------------------------------------------------------------------------ Sales by Segment (in millions)
First Quarter 1995 1994 Change Consumer Imaging Inside the U.S. $ 486 $ 331 +47% Outside the U.S. 781 668 +17 ------ ------ --- Total Consumer Imaging 1,267 999 +27 ------ ------ --- Commercial Imaging Inside the U.S. 925 909 +2 Outside the U.S. 952 847 +12 ------ ------ --- Total Commercial Imaging 1,877 1,756 +7 ------ ------ --- Deduct Intersegment Sales (7) 0 ------ ------ -- Total Worldwide $3,137 $2,755 +14% ====== ====== ===
7 SEGMENT SALES In the Consumer Imaging segment, sales for the first quarter of 1995 to customers inside the U.S. increased 47% over sales for the first quarter of 1994. Excluding the sales of Qualex, sales were up 10% over a year ago, due to increased volumes. Sales to customers outside the U.S. recorded a 17% increase for the first quarter of 1995 when compared with the first quarter of 1994. The favorable effects of solid gains in unit volumes and foreign currency rate changes were only slightly offset by lower effective selling prices. Currency changes against the U.S. dollar favorably affected 1995 sales by approximately $49 million. Worldwide volume gains were led by Ektacolor papers and Kodacolor films. In the Commercial Imaging segment, 1995 first quarter sales inside the U.S. increased 2% when compared with sales for the first quarter of 1994. Outside the U.S., sales in the first quarter of 1995 increased 12% over sales for the comparable period a year ago as the favorable effects of foreign currency rate changes and higher volumes were only slightly offset by lower effective selling prices. Currency changes against the U.S. dollar favorably affected 1995 sales by approximately $78 million. Worldwide sales increases were led by printing and professional imaging, and office imaging products. - - ------------------------------------------------------------------------------ COSTS AND EXPENSES
First Quarter (in millions) 1995 1994 Change Gross profit $1,524 $1,285 +19% Percent of Sales 48.6% 46.7% Selling, general and administrative expenses $ 895 $ 747 +20% Percent of Sales 28.5% 27.1% Research and development costs $ 219 $ 204 +7% Percent of Sales 7.0% 7.4%
The improvement in gross profit as a percent of sales from 46.7% in 1994 to 48.6% in 1995 was primarily due to manufacturing productivity and increased volumes. Excluding the SG&A expenses of Qualex, SG&A expenditures were up 14% over the first quarter of 1994. This increase in SG&A expenditures was primarily due to cost escalation, the effect of higher volumes on distribution costs, the unfavorable effects of foreign currency rate changes on locally incurred costs and higher advertising expenditures. - - ------------------------------------------------------------------------------ Earnings from Operations by Industry Segment
(in millions) First Quarter 1995 1994 Change Consumer Imaging $ 152 $ 103 +48% Percent of Sales 12.0% 10.3% Commercial Imaging $ 264 $ 224 +18% Percent of Sales 14.1% 12.8% ----- ----- ---- Total $ 416 $ 327 +27% ===== ===== ====
8 - - ------------------------------------------------------------------------------ SEGMENT EARNINGS Operating earnings for the Consumer Imaging segment for the first quarter of 1995 increased 48% over the first quarter of last year as the favorable effects from higher volumes, manufacturing productivity and foreign currency rate changes were only partially offset by increased SG&A expenses, cost escalation and lower effective selling prices. Commercial Imaging segment operating earnings for the 1995 first quarter increased 18% when compared with the first quarter of a year ago, as the benefits from increased unit volumes and manufacturing productivity were only partially offset by cost escalation, lower effective selling prices and increased SG&A expenses. - - ------------------------------------------------------------------------------ OTHER REVENUES AND COSTS Earnings from equity interests and other revenues for the first quarter of 1995 were higher than the 1994 first quarter primarily due to increased investment income earned on higher average cash balances and increased earnings from equity interests. Interest expense for the 1995 first quarter decreased when compared with the 1994 first quarter due to lower average borrowings. The decrease in other charges in 1995 when compared with 1994 is primarily due to lower net losses in 1995 from foreign exchange transactions and the translation of net monetary items in highly inflationary economies. - - ------------------------------------------------------------------------------ CASH DIVIDENDS Cash dividends of 40 cents per share were declared on the Company's common stock during the first quarters of 1995 and 1994. Total cash dividends declared in the first quarters of 1995 and 1994 were $136 million and $132 million, respectively. FINANCIAL POSITION Cash and marketable securities were $633 million at the end of the first quarter of 1995, compared with $2,068 million at year-end 1994. The decrease is primarily due to tax payments of approximately $1.3 billion related to the divestiture of the non-imaging health businesses. Working capital at the end of the quarter increased to $2,115 million compared with $1,948 million at year-end 1994. Projected operating cash flows are expected to be adequate to support normal business operations, planned capital expenditures and dividend payments in 1995. CAPITAL ADDITIONS Capital additions for the first quarter of 1995 were $238 million compared with $149 million for the first quarter of 1994. The provision for depreciation for the first quarter of 1995 was $202 million, compared with $176 million for the first quarter of last year. - - ------------------------------------------------------------------------------ 9 Part II. OTHER INFORMATION Item 1. Legal Proceedings The Company is participating in the Environmental Protection Agency's (EPA) Toxic Substances Control Act (TSCA) Section 8 (e) Compliance Audit Program. As a participant, the Company has agreed to audit its files for materials which under current EPA guidelines would be subject to notification under Section 8 (e) of TSCA and to pay stipulated penalties for each report submitted under this program. The Company anticipates that its liability under the Program will be $1,000,000. In addition to the foregoing environmental action, the Company has been designated as a potentially responsible party (PRP) under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (the Superfund law), or under similar state laws, for environmental assessment and cleanup costs as the result of the Company's alleged arrangements for disposal of hazardous substances at approximately twenty-five Superfund sites. With respect to each of these sites, the Company's actual or potential allocated share of responsibility is small. Furthermore, numerous other PRPs have similarly been designated at these sites and, although the law imposes joint and several liability on PRPs, as a practical matter costs are shared with other PRPs. Settlements and costs paid by the Company in Superfund matters to date have not been material. Future costs are also not expected to be material to the Company's financial condition or results of operations. Item 6. Exhibits and Reports on Form 8-K (a) Exhibits required as part of this report are listed in the index appearing on page 11. (b) Reports on Form 8-K Eastman Kodak Company filed the following Current Report on Form 8-K during the first quarter of 1995: 1. Current Report on Form 8-K dated December 31, 1994 (filed January 9, 1995). The 8-K reported Items 2 and 7 and included under Item 7 (b) financial data, consolidated financial statements, financial statement schedules, and additional data to provide historical financial information reclassifying the results of the non-imaging health businesses which the Company divested in 1994. 10 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. EASTMAN KODAK COMPANY (Registrant) David J. FitzPatrick, Controller Date April 27, 1995 11 Eastman Kodak Company and Subsidiary Companies Index to Exhibits Exhibit Number Page No. (11) Statement Re Computation of Earnings Per Common Share 12 (27) Financial Data Schedule, Exhibit (27) - Submitted with the Edgar filing as a second document to this Form 10-Q 12 Eastman Kodak Company and Subsidiary Companies Exhibit (11) Computation of Earnings Per Common Share
First Quarter 1995 1994 (in millions, except per share amounts) PRIMARY: Earnings from continuing operations before income taxes $ 415 $ 230 Provision for income taxes from continuing operations 153 85 ------ ------ Earnings from continuing operations before extraordinary item 262 145 Loss from discontinued operations - (51) ------ ------ Earnings before extraordinary item 262 94 Extraordinary item - (12) ------ ------ Net Earnings $ 262 $ 82 ====== ====== Average number of common shares outstanding 340.0 330.7 ------ ------ Primary earnings per share from continuing operations before extraordinary item $ .77 $ .44 Primary loss per share from discontinued operations - (.15) ------ ------ Primary earnings per share before extraordinary item .77 .29 Extraordinary item - (.04) ------ ------ Primary earnings per share $ .77 $ .25 ====== ====== First Quarter 1995 1994 (in millions, except per share amounts) FULLY DILUTED: Earnings from continuing operations before extraordinary item $ 262 $ 145 Add after-tax interest expense applicable to: 6 3/8% convertible debentures (1) - - Zero coupon convertible debentures (1) - - ----- ----- Adjusted earnings from continuing operations before extraordinary item 262 145 Loss from discontinued operations - (51) ----- ----- Adjusted earnings before extraordinary item 262 94 Extraordinary item - (12) ----- ----- Adjusted net earnings $ 262 $ 82 ===== ===== (1) 6 3/8% convertible debentures and zero coupon convertible debentures were anti-dilutive in first quarter 1994 and repaid in 1994.
13 Eastman Kodak Company and Subsidiary Companies Exhibit (11) (Continued) Computation of Earnings Per Common Share
First Quarter 1995 1994 (in millions, except per share amounts) Average number of common shares outstanding 340.0 330.7 Add-incremental shares under option 6.0 3.4 Add-incremental shares applicable to: 6 3/8% convertible debentures (1) - - Zero coupon convertible debentures (1) - - ----- ----- Adjusted average number of shares outstanding 346.0 334.1 ----- ----- Fully diluted earnings per share from continuing operations before extraordinary item $ .76 $ .43 Fully diluted loss per share from discontinued operations - (.15) ----- ----- Fully diluted earnings per share before extraordinary item .76 .28 Extraordinary item - (.04) ----- ----- Fully diluted earnings per share $ .76 $ .24 ===== ===== (1) 6 3/8% convertible debentures and zero coupon convertible debentures were anti-dilutive in first quarter 1994 and repaid in 1994.
 

5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FIRST QUARTER 1995 FORM 10-Q OF EASTMAN KODAK COMPANY, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 0000031235 EASTMAN KODAK COMPANY 1,000,000 U.S. DOLLARS 3-MOS DEC-31-1995 JAN-01-1995 MAR-31-1995 1.0 573 60 2,855 117 1,834 6,302 12,667 7,261 13,693 4,187 652 967 0 0 3,251 13,693 3,137 3,209 1,613 1,613 1,162 0 19 415 153 262 0 0 0 262 0.77 0.76